MarketCap
Facebook
X
TelegramAnnual report 2025
added 02-17-2026
CONMED Corporation Operating Income 2011-2026 | CNMD
Operating profit (also called operating income or profit from core activities) is a financial metric that reflects a company's profit from its main operational activities before interest expenses and taxes are taken into account.
FormulaOperating profit = Revenue – Operating expensesFeatures of the metric
- Evaluates business efficiency
Shows how well the company controls its production and administrative costs. - Independent of financial structure
Excludes the impact of debt burden (interest) and taxes, allowing objective comparison of companies. - Main source for growth
High operating profit provides resources for investments, business expansion, and increased competitiveness.
If a company shows strong operating profit, it signals to investors that the core business is operating efficiently, even if net profit is temporarily reduced due to debt or tax burden.
Annual Operating Income CONMED Corporation
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 103 M | 200 M | 121 M | 70.1 M | 110 M | 46 M | 79.1 M | 71.3 M | 46.9 M | 37.7 M | 51.2 M | 52.8 M | 56.5 M | 65.2 M | 8.27 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 200 M | 8.27 M | 74.6 M |
Quarterly Operating Income CONMED Corporation
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 11.9 M | 38.2 M | 16 M | 65.7 M | 47.1 M | 35 M | 30.3 M | 27.4 M | 12.7 M | - | 24.2 M | 24.5 M | 22.4 M | - | 26.7 M | 25.7 M | 20.1 M | - | 29.4 M | -21.2 M | 13.2 M | - | 20.9 M | 18.7 M | 11.6 M | - | 11.5 M | 16.7 M | 17.3 M | - | 13.5 M | 12.8 M | -2.49 M | - | 13.8 M | 7.68 M | 3.54 M | - | 14.8 M | 12.4 M | 11 M | - | 2.45 M | 15.9 M | 17.3 M | - | 8.8 M | 15.7 M | 15.9 M | - | 14.1 M | 17.1 M | 17 M | - | 15.9 M | 16.7 M | 17.3 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 65.7 M | -21.2 M | 17.9 M |
Operating Income of other stocks in the Medical devices industry
| Issuer | Operating Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
BioSig Technologies
BSGM
|
-12.9 M | - | 37.08 % | $ 85.7 M |  USA |
 |
Axonics Modulation Technologies
AXNX
|
-64.9 M | - | - | $ 3.31 B | USA |
 |
Aziyo Biologics
AZYO
|
-26.9 M | - | 1.37 % | $ 20.5 M | USA |
 |
Acutus Medical
AFIB
|
-11.7 M | - | -26.83 % | $ 2.62 M | USA |
 |
Allied Healthcare Products
AHPI
|
-1.27 M | - | 3.58 % | $ 2.21 M | USA |
 |
Second Sight Medical Products
EYES
|
-24.7 M | - | -0.97 % | $ 54.4 M | USA |
 |
Insulet Corporation
PODD
|
474 M | $ 215.63 | -4.38 % | $ 15.2 B | USA |
 |
Profound Medical Corp.
PROF
|
-30.3 M | $ 5.78 | 12.23 % | $ 180 M |  Canada |
 |
Conformis
CFMS
|
-46.3 M | - | - | $ 16.4 M | USA |
 |
Quanterix Corporation
QTRX
|
-126 M | $ 3.92 | 2.62 % | $ 167 M | USA |
 |
Integra LifeSciences Holdings Corporation
IART
|
28.4 M | $ 9.54 | - | $ 735 M | USA |
 |
AVITA Medical
RCEL
|
-42.5 M | $ 3.97 | 3.39 % | $ 111 M |  Australia |
 |
Cardiovascular Systems
CSII
|
-35.8 M | - | 0.15 % | $ 844 M | USA |
 |
IRIDEX Corporation
IRIX
|
-10 M | $ 1.33 | -1.48 % | $ 21.5 M | USA |
 |
Apollo Endosurgery
APEN
|
-31.4 M | - | - | $ 475 M | USA |
 |
Avinger
AVGR
|
-16.6 M | - | -20.74 % | $ 369 K | USA |
 |
Sintx Technologies
SINT
|
-10.7 M | $ 2.55 | -0.77 % | $ 7.07 M | USA |
 |
Smith & Nephew plc
SNN
|
593 M | $ 32.43 | 0.82 % | $ 23.8 B |  Britain |
 |
NanoVibronix
NAOV
|
-3.58 M | - | - | $ 1.08 M | USA |
 |
Electromed
ELMD
|
9.66 M | $ 24.73 | 0.12 % | $ 209 M | USA |
 |
Sensus Healthcare
SRTS
|
-10.3 M | $ 4.21 | 6.31 % | $ 68.7 M | USA |
 |
Neovasc
NVCN
|
-31.1 M | - | - | $ 111 M | Canada |
 |
Tactile Systems Technology
TCMD
|
29.3 M | $ 26.86 | -0.02 % | $ 614 M | USA |
 |
TELA Bio
TELA
|
-44.1 M | $ 0.7 | -7.88 % | $ 16 M | USA |
 |
Cytosorbents Corporation
CTSO
|
-16.8 M | $ 0.67 | -3.33 % | $ 36.5 M | USA |
 |
Aethlon Medical
AEMD
|
-9.34 M | $ 2.38 | 10.12 % | $ 3.71 M | USA |
 |
BIOLASE
BIOL
|
-17.9 M | - | -13.19 % | $ 166 K | USA |
 |
Tandem Diabetes Care
TNDM
|
8.29 M | $ 24.02 | -2.02 % | $ 1.63 B | USA |
 |
InspireMD
NSPR
|
-49.6 M | $ 1.76 | -0.56 % | $ 113 M |  Israel |
 |
AdaptHealth Corp.
AHCO
|
90.9 M | $ 11.33 | -1.31 % | $ 1.53 B | USA |
 |
Penumbra
PEN
|
189 M | $ 336.05 | 0.54 % | $ 13.1 B | USA |
 |
Myomo
MYO
|
-14.4 M | $ 0.69 | -0.33 % | $ 28.9 M | USA |
 |
Nano-X Imaging Ltd.
NNOX
|
-56.7 M | $ 2.28 | -5.0 % | $ 134 M | Israel |
 |
Invacare Corporation
IVC
|
-80.5 M | - | - | $ 24.7 M | USA |
 |
EDAP TMS S.A.
EDAP
|
-20.5 M | $ 3.7 | -5.37 % | $ 138 M |  France |
 |
OrthoPediatrics Corp.
KIDS
|
-39.2 M | $ 16.22 | 1.95 % | $ 381 M | USA |
 |
Outset Medical
OM
|
-66.7 M | $ 3.49 | -1.27 % | $ 53.1 K | USA |
 |
Inspire Medical Systems
INSP
|
51 M | $ 51.29 | -1.52 % | $ 1.51 B | USA |
 |
Pulmonx Corporation
LUNG
|
-53.7 M | $ 1.29 | -1.53 % | $ 52.5 M | USA |